Effects of sacubitril/valsartan versus olmesartan on central hemodynamics in the elderly with systolic Hypertension

Hypertension

Volumn 69, Issue 3, 2017, Pages 411-420

  Williams, Bryan ^a,b   Cockcroft, John R ^c   Kario, Kazuomi ^d   Zappe, Dion H ^e   Brunel, Patrick C ^e   Wang, Qian ^f   Guo, Weinong ^e  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Camden and Islington National Health Service Foundation Trust   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d JICHI MEDICAL UNIVERSITY   (Japan)

^e NOVARTIS PHARMA AG   (Switzerland)

^f Beijing Novartis Pharma Co Ltd   (China)

Author keywords

central pressure; elderly; sacubitril valsartan; systolic hypertension

Indexed keywords

ACETYLSALICYLIC ACID; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMLODIPINE; BIGUANIDE DERIVATIVE; CREATININE; CYCLIC GMP; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OLMESARTAN; SACUBITRIL PLUS VALSARTAN; AMINOBUTYRIC ACID DERIVATIVE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; IMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE;

ABDOMINAL PAIN; ADD ON THERAPY; ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; AORTA PRESSURE; ARTERIAL STIFFNESS; ARTHRALGIA; ARTICLE; BACKACHE; BLOOD PRESSURE MONITORING; BODY MASS; BRACHIAL ARTERY; CAROTID ARTERY PULSE; CONTROLLED STUDY; COUGHING; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FEMORAL ARTERY; HEADACHE; HEART RATE; HEMODYNAMICS; HUMAN; HYPOTENSION; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; PERIPHERAL EDEMA; POST HOC ANALYSIS; PRIORITY JOURNAL; PULSE PRESSURE; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; UPPER RESPIRATORY TRACT INFECTION; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECTS; FOLLOW UP; HYPERTENSION; MIDDLE AGED; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; SYSTOLE; TIME FACTOR; TREATMENT OUTCOME;

AGED; AMINOBUTYRATES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN RECEPTOR ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HEMODYNAMICS; HUMANS; HYPERTENSION; IMIDAZOLES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SYSTOLE; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME;

EID: 85009742341     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.116.08556     Document Type: Article

References (45)

1. Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S, White IR, Caulfield MJ, Deanfield JE, Smeeth L, Williams B, Hingorani A, Hemingway H., Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people. Lancet 2014 383 1899 1911. doi: 10.1016/S0140-6736(14)60685-1
2. Williams B, Lindholm LH, Sever P., Systolic pressure is all that matters. Lancet 2008 371 2219 2221. doi: 10.1016/S0140-6736(08)60804-1
3. Franklin SS., Pulse pressure as a risk factor. Clin Exp Hypertens 2004 26 645 652
4. Bangalore S, Messerli FH, Franklin SS, Mancia G, Champion A, Pepine CJ., Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-Trandolapril STudy (INVEST) analysis. Eur Heart J 2009 30 1395 1401. doi: 10.1093/eurheartj/ehp109
5. Franklin SS, Lopez VA, Wong ND, Mitchell GF, Larson MG, Vasan RS, Levy D., Single versus combined blood pressure components and risk for cardiovascular disease: the Framingham Heart Study. Circulation 2009 119 243 250. doi: 10.1161/CIRCULATIONAHA.108.797936
6. Haider AW, Larson MG, Franklin SS, Levy D, Framingham Heart Study Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the Framingham Heart Study. Ann Intern Med 2003 138 10 16
7. Domanski M, Mitchell G, Pfeffer M, Neaton JD, Norman J, Svendsen K, Grimm R, Cohen J, Stamler J, MRFIT Research Group Pulse pressure and cardiovascular disease-related mortality: follow-up study of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 2002 287 2677 2683
8. Chirinos JA, Khan A, Bansal N, CRIC Study Investigators; CRIC Study Investigators Arterial stiffness, central pressures, and incident hospitalized heart failure in the chronic renal insufficiency cohort study. Circ Heart Fail 2014 7 709 716. doi: 10.1161/CIRCHEARTFAILURE.113.001041
9. Kannel WB, Wolf PA, McGee DL, Dawber TR, McNamara P, Castelli WP., Systolic blood pressure, arterial rigidity, and risk of stroke. The Framingham study. JAMA 1981 245 1225 1229
10. Townsend RR., Arterial stiffness and chronic kidney disease: lessons from the Chronic Renal Insufficiency Cohort study. Curr Opin Nephrol Hypertens 2015 24 47 53. doi: 10.1097/MNH.0000000000000086
11. Staessen JA, Thijs L, Fagard R, O'Brien ET, Clement D, de Leeuw PW, Mancia G, Nachev C, Palatini P, Parati G, Tuomilehto J, Webster J., Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA 1999 282 539 546
12. Hansen TW, Li Y, Boggia J, Thijs L, Richart T, Staessen JA., Predictive role of the nighttime blood pressure. Hypertension 2011 57 3 10. doi: 10.1161/HYPERTENSIONAHA.109.133900
13. Fan HQ, Li Y, Thijs L, International Database on Ambulatory Blood Pressure In Relation to Cardiovascular Outcomes Investigators Prognostic value of isolated nocturnal hypertension on ambulatory measurement in 8711 individuals from 10 populations. J Hypertens 2010 28 2036 2045. doi: 10.1097/HJH.0b013e32833b49fe
14. Fagard RH, Celis H, Thijs L, Staessen JA, Clement DL, De Buyzere ML, De Bacquer DA., Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension 2008 51 55 61. doi: 10.1161/HYPERTENSIONAHA.107.100727
15. Dolan E, Stanton A, Thijs L, Hinedi K, Atkins N, McClory S, Den Hond E, McCormack P, Staessen JA, O'Brien E., Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension 2005 46 156 161. doi: 10.1161/01.HYP.0000170138.56903.7a
16. Mitchell GF, Izzo JL Jr, Lacourcière Y, Ouellet JP, Neutel J, Qian C, Kerwin LJ, Block AJ, Pfeffer MA., Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension: results of the conduit hemodynamics of omapatrilat international research study. Circulation 2002 105 2955 2961
17. Desai AS, Mitchell GF, Fang JC, Creager MA., Central aortic stiffness is increased in patients with heart failure and preserved ejection fraction. J Card Fail 2009 15 658 664. doi: 10.1016/j.cardfail.2009.03.006
18. Lam CS, Gona P, Larson MG, Aragam J, Lee DS, Mitchell GF, Levy D, Cheng S, Benjamin EJ, Vasan RS., Aortic root remodeling and risk of heart failure in the Framingham Heart study. JACC Heart Fail 2013 1 79 83. doi: 10.1016/j.jchf.2012.10.003
19. Pepine CJ, Nichols WW, Conti CR., Aortic input impedance in heart failure. Circulation 1978 58 3 pt 1 460 465
20. O'Rourke MF, Avolio A, Safar M, Nichols W., Changes in the central arterial pressure pulse with aging. J Am Coll Cardiol 2010 55 2183. author reply 2184. doi: 10.1016/j.jacc.2010.01.037
21. Dahlöf B, Lindholm LH, Hansson L, Scherstén B, Ekbom T, Wester PO., Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991 338 1281 1285
22. Staessen JA, Fagard R, Thijs L, Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997 350 757 764
23. Beckett NS, Peters R, Fletcher AE, HYVET Study Group Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008 358 1887 1898. doi: 10.1056/NEJMoa0801369
24. Wright JT Jr, Williamson JD, Whelton PK, A randomized trial of intensive versus standard blood-pressure control. New Engl J Med 2015 373 2103 2116. doi: 10.1056/NEJMoa1511939
25. Vlachopoulos C, Aznaouridis K, O'Rourke MF, Safar ME, Baou K, Stefanadis C., Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-Analysis. Eur Heart J 2010 31 1865 1871. doi: 10.1093/eurheartj/ehq024
26. McEniery CM, Cockcroft JR, Roman MJ, Franklin SS, Wilkinson IB., Central blood pressure: current evidence and clinical importance. Eur Heart J 2014 35 1719 1725. doi: 10.1093/eurheartj/eht565
27. Williams B, Lacy PS., Central aortic pressure and clinical outcomes. J Hypertens 2009 27 1123 1125. doi: 10.1097/HJH.0b013e32832b6566
28. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O'Rourke M, CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006 113 1213 1225. doi: 10.1161/CIRCULATIONAHA.105.595496
29. Boutouyrie P, Achouba A, Trunet P, Laurent S, EXPLOR Trialist Group Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-Atenolol combination: the EXPLOR study. Hypertension 2010 55 1314 1322. doi: 10.1161/HYPERTENSIONAHA.109.148999
30. Gu J, Noe A, Chandra P, Al-Fayoumi S, Ligueros-Saylan M, Sarangapani R, Maahs S, Ksander G, Rigel DF, Jeng AY, Lin TH, Zheng W, Dole WP., Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-Acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol 2010 50 401 414. doi: 10.1177/0091270009343932
31. Kario K, Sun N, Chiang FT, Supasyndh O, Baek SH, Inubushi-Molessa A, Zhang Y, Gotou H, Lefkowitz M, Zhang J., Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study. Hypertension 2014 63 698 705. doi: 10.1161/HYPERTENSIONAHA.113.02002
32. Ruilope LM, Dukat A, Böhm M, Lacourcière Y, Gong J, Lefkowitz MP., Blood-pressure reduction with LCZ696, a novel dual-Acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 2010 375 1255 1266. doi: 10.1016/S0140-6736(09)61966-8
33. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Investigators and Committees Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014 371 993 1004. doi: 10.1056/NEJMoa1409077
34. Williams B, Cockcroft JR, Kario K, Zappe DH, Cardenas P, Hester A, Brunel P, Zhang J., Rationale and study design of the Prospective comparison of Angiotensin Receptor neprilysin inhibitor with Angiotensin receptor blocker MEasuring arterial sTiffness in the eldERly (PARAMETER) study. BMJ Open 2014 4 e004254. doi: 10.1136/bmjopen-2013-004254
35. Butlin M, Qasem A, Avolio AP., Estimation of central aortic pressure waveform features derived from the brachial cuff volume displacement waveform. Conf Proc IEEE Eng Med Biol Soc 2012 2012 2591 2594. doi: 10.1109/EMBC.2012.6346494
36. Williams B, Lacy PS, Baschiera F, Brunel P, Düsing R., Novel description of the 24-hour circadian rhythms of brachial versus central aortic blood pressure and the impact of blood pressure treatment in a randomized controlled clinical trial: the Ambulatory Central Aortic Pressure (AmCAP) Study. Hypertension 2013 61 1168 1176. doi: 10.1161/HYPERTENSIONAHA.111.00763
37. Williams B., Hypertension and the "J-curve". J Am Coll Cardiol 2009 54 1835 1836. doi: 10.1016/j.jacc.2009.06.043
38. Packer M, McMurray JJ, Desai AS, PARADIGM-HF Investigators and Coordinators Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 2015 131 54 61. doi: 10.1161/CIRCULATIONAHA.114.013748
39. Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, Lefkowitz M, Packer M, McMurray JJ, Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012 380 1387 1395. doi: 10.1016/S0140-6736(12)61227-6
40. The Reference Values for Arterial Stiffness' Collaboration Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: 'establishing normal and reference values'. Eur Heart J 2010 31 2338 2350. doi: 10.1093/eurheartj/ehq165
41. Laurent S, Boutouyrie P, Vascular Mechanism Collaboration Dose-dependent arterial destiffening and inward remodeling after olmesartan in hypertensives with metabolic syndrome. Hypertension 2014 64 709 716. doi: 10.1161/HYPERTENSIONAHA.114.03282
42. Ruilope LM, SEVITENSION Study Investigators Fixed-combination olmesartan/amlodipine was superior to perindopril + amlodipine in reducing central systolic blood pressure in hypertensive patients with diabetes. J Clin Hypertens (Greenwich) 2016 18 528 535. doi: 10.1111/jch.12673
43. Giles TD, Oparil S, Silfani TN, Wang A, Walker JF., Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension. J Clin Hypertens (Greenwich) 2007 9 187 195. doi: 10.1111/j.1524-6175.2007.06395.x
44. Kjeldsen S, Feldman RD, Lisheng L, Mourad JJ, Chiang CE, Zhang W, Wu Z, Li W, Williams B., Updated national and international hypertension guidelines: a review of current recommendations. Drugs 2014 74 2033 2051. doi: 10.1007/s40265-014-0306-5
45. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K., Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-Analysis. Lancet 2016 387 957 967. doi: 10.1016/S0140-6736(15)01225-8